Lurbinectedin is a chemotherapy drug that has been approved for the treatment of small cell lung cancer (SCLC) in the European Union and is currently undergoing clinical trials in the United States. There is ongoing research to determine the effectiveness of combining lurbinectedin with immunotherapy drugs such as pembrolizumab.

A clinical trial (NCT04358237) is currently underway to investigate the safety and efficacy of combining lurbinectedin with pembrolizumab in patients with advanced solid tumors. Preliminary results from this trial have shown that the combination therapy is safe and effective in treating relapsed SCLC. The trial is ongoing, and further results are expected to be published in the future [3].

While the combination of lurbinectedin and immunotherapy is still being studied, it is important to note that the use of immunotherapy in cancer treatment has shown promising results in recent years. Immunotherapy works by stimulating the body's immune system to recognize and attack cancer cells, and it has been approved for the treatment of various types of cancer.

In conclusion, combining lurbinectedin with immunotherapy drugs such as pembrolizumab is a promising area of research for the treatment of advanced solid tumors, including SCLC. Ongoing clinical trials are investigating the safety and efficacy of this combination therapy, and preliminary results have shown promising results [3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.clinicaltrials.gov/ct2/show/NCT04358237
[3] https://www.cancernetwork.com/view/preliminary-results-show-second-line-lurbinectedin-plus-pembrolizumab-safe-effective-in-relapsed-sclc